•	Can Seaweed Mend a Broken Heart? Cynthia Graber Scientific American April 7, 2008 New research indicates that an alginate-based biomaterial injected into heart attack victims may stave off further damage
•	BL-1040 featured on Channel 10 Evening News (Hebrew) Hila Alroy Channel 10 TV March 23, 2008
•	BioLineRx jumps after patient gets heart treatment Alisa Odenheimer Bloomberg March 24, 2008 BioLineRx Ltd., the Israeli drug developer planning a US stock-market listing, advanced the most ever in Tel Aviv trading on Sunday after the first human patient to be treated with its heart-attack-treatment compound was "successfully" discharged from a German hospital.
•	BioLineRx seeks EU human trials for innovative heart-support gel Clinica June 15, 2007
•	Israel’s Public Venture Market Roger Longman In Vivo Blog June 13, 2007 Israeli biotech is bursting with ideas—or so IN VIVO Blog discovered at the country’s annual biotech fest in Tel Aviv, ILSI Biomed Israel 2007.
•	BioLineRx - Israel's biotech supermarket David Brinn ISRAEL21c June 3, 2007 The people at leading Israeli biotech company BioLineRx must have a lot of baskets in their Jerusalem offices. Because, unlike most biotech companies which put all their eggs in one basket by focusing on a compound and hoping to develop it into a blockbuster drug, BioLineRx is taking its eggs and spreading them around in a myriad of baskets. And the strategy is paying off.
•	An Israeli Biotech Company Plays the Field Neal Sandler Business Week March 13, 2007 Flush with investors' capital, BioLineRX screens hundreds of promising compounds then develops a handful that might make profitable drugs
•	All lined up Steve Edelson & Stacy Lawrence BioCentury February 12, 2007 The other first was BioLineRx (Tel Aviv:BLRX), which raised $50 million through the sale of 28.7 million shares at $1.74, making it the largest biotech IPO ever in Israel. The offering gave BLRX a valuation of $113 million.
•	Bioline Therapeutics Big Success in Tel Aviv Neal Sandler Red Herring February 9, 2007 IPO fever has also caught on in Tel Aviv. Bioline Therapeutics became the latest to catch it, raising $50 million in the largest ever IPO by a biotechnology firm in the local market. The company sold 45 percent of its shares.
•	BioLineRx VCs To Participate In $50M IPO Jonathan Matsey Dow Jones VentureWire February 8, 2007 BioLineRx Ltd., an Israeli drug developer, said that it will be going public Monday on the Tel Aviv Stock Exchange - and its venture capitalists will be providing $10 million in the process.
•	BioLineRx Prices $50M IPO, Listing On Tel Aviv Exchange Jennifer Boggs BioWorld Today Febraury 8, 2007 Israeli drug development firm BioLineRx Ltd. gained a listing on the Tel Aviv Stock Exchange and brought in $50 million in an oversubscribed initial public offering.
•	BioLineRx raises $50m. in TASE's largest biomedical IPO LAURA RHEINHEIMER Jerusalem Post February 8, 2007 BioLineRx Ltd. on Wednesday priced the largest ever initial public offering of a biomedical company on the Tel Aviv Stock Exchange, raising a total of NIS 211 million, or $50m.
•	BioLineRx Raises $50 Million in Share Offering in Tel Aviv Tal Barak Bloomberg February 8, 2007 BioLineRx Ltd., a drug-development company that's 16 percent owned by Teva Pharmaceutical Industries Ltd., raised $50 million in an initial share sale on the Tel Aviv Stock Exchange yesterday.
•	Israel's BioLineRx in $50 mln IPO Sergio Tjong-Alvares Reuters February 7, 2007
•	Latest BioLineRx In-License: Oral Peptide Drug for Obesity Aaron Lorenzo BioWorld Today July 17, 2006
•	Bioline acquires rights to Gevys pain treatment Gali Weinreb Globes May 26, 2006 The drug for the treatment of acute and chronic pain will go on the market from 2008.
•	RH 100 Europe: Biosciences Red Herring May 8, 2006 Red Herring magazine’s top private European bioscience companies for 2006.
•	At BIO 2006 Rick Mullin, Senior Editor Chemical & Engineering News May 8, 2006 Biotech drug companies report recent milestones on the road to breakthrough therapies.
•	Israel’s Biolinerx looks for international opportunities Lisa Davies Scrip World Pharmaceutical News April 19, 2006 Biolinerx, a private Israeli biotech company founded in 2003 by Teva Pharmaceutical Industries and others, is looking for opportunities internationally.
•	BioLineRx: It’s Built To Power Drugs Through Development Aaron Lorenzo, Washington Editor BioWorld Today March 6, 2006 BioLineRx Ltd. isn’t your everyday biotech start-up. The reason? A quick glance at the two-year-old firm’s portfolio reveals 10 products, some of which are in late-stage preclinical research and expected to move ...
•	BioLineRx Backs Project Developing Immunization Against Melanoma October 5, 2004 Special-purpose drug company BioLineRx yesterday announced the establishment of a new startup to focus on the development of an immunization against melanoma skin cancer.
•	BioCentury Emerging Company Profile - BioLineRx: From ridiculous to the sublime September 20, 2004 Many regions have more biotech companies and projects than can be funded by the local venture community. BioLineRx Ltd. was founded to find the nuggets in the crowded Israeli biotech landscape and advance them through Phase II trials for subsequent out-licensing.
•	BioLineRx to Incubate 6 Projects A Year BioIsrael.com March, 2004 Two years ago the Israeli government conducted an international tender to choose two consortiums that would receive funding from the Ministry of Industry and Trade to found biotechnology incubators.